IFNAR2 and systemic lupus erythematosus: The exact role of type I IFN in the pathogenesis of SLE is still being defined and abrogating this pathway may not lead to decreases in disease manifestations, as evidence from recent clinical trials using interferon receptor blocker Anifrolumab and the plasmacytoid dendritic cells specific receptor antibody BIIB05933,34.